Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XERS Stock Forecast 2026-2027
$5.92
Current Price
$1.02B
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to XERS Price Targets
+204.1%
To High Target of $18.00
+68.9%
To Median Target of $10.00
+35.1%
To Low Target of $8.00
XERS Price Momentum
-2.0%
1 Week Change
+5.7%
1 Month Change
+36.7%
1 Year Change
-24.6%
Year-to-Date Change
-41.3%
From 52W High of $10.08
+55.4%
From 52W Low of $3.81
📊 TOP ANALYST CALLS
Did XERS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Xeris is one of their latest high-conviction picks.
Latest XERS Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, XERS has a bullish consensus with a median price target of $10.00 (ranging from $8.00 to $18.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $5.92, the median forecast implies a 68.9% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Leland Gershell at Oppenheimer, projecting a 204.1% upside. Conversely, the most conservative target is provided by David Amsellem at Piper Sandler, suggesting a 35.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XERS Analyst Ratings
6
Buy
1
Hold
0
Sell
XERS Price Target Range
Low
$8.00
Average
$10.00
High
$18.00
Current: $5.92
Latest XERS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XERS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 2, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $10.00 |
| Jan 9, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $10.00 |
| Dec 9, 2025 | Barclays | Glen Santangelo | Overweight | Initiates | $9.00 |
| Nov 7, 2025 | Oppenheimer | Leland Gershell | Outperform | Maintains | $18.00 |
| Nov 7, 2025 | Piper Sandler | David Amsellem | Neutral | Maintains | $8.00 |
| Nov 7, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Maintains | $10.00 |
| Oct 29, 2025 | Oppenheimer | Leland Gershell | Outperform | Maintains | $18.00 |
| Sep 17, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 19, 2025 | Leerink Partners | Roanna Ruiz | Outperform | Maintains | $9.00 |
| Aug 12, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $10.00 |
| Aug 8, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| Aug 8, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Jun 5, 2025 | Leerink Partners | Outperform | Maintains | $N/A | |
| May 9, 2025 | Oppenheimer | Leland Gershell | Outperform | Maintains | $7.00 |
| Mar 7, 2025 | Piper Sandler | David Amsellem | Neutral | Reiterates | $4.00 |
| Mar 7, 2025 | Leerink Partners | Roanna Ruiz | Outperform | Maintains | $6.00 |
| Mar 7, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $6.50 |
| Mar 7, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $8.00 |
| Jan 29, 2025 | Jefferies | Glen Santangelo | Buy | Reiterates | $6.00 |
| Nov 11, 2024 | Piper Sandler | David Amsellem | Neutral | Downgrade | $3.00 |
Xeris Biopharma Holdings, Inc. (XERS) Competitors
The following stocks are similar to Xeris based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Xeris Biopharma Holdings, Inc. (XERS) Financial Data
Valuation Metrics
Market Cap
$1.02B
Enterprise Value
$1.19B
P/E Ratio
N/A
PEG Ratio
16.3x
Price/Sales
3.6x
Growth & Margins
Revenue Growth (YoY)
+42.8%
Gross Margin
+87.2%
Operating Margin
+19.5%
Net Margin
+0.2%
EPS Growth
+42.8%
Financial Health
Cash/Price Ratio
+10.9%
Current Ratio
2.2x
Debt/Equity
1,885.4x
ROE
+4.0%
ROA
+4.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Xeris Biopharma Holdings, Inc. (XERS) Business Model
About Xeris Biopharma Holdings, Inc.
What They Do
Develops therapies for chronic endocrine and neurological conditions.
Business Model
The company generates revenue through the commercialization of its biopharmaceutical products, which include Recorlev, Gvoke, and Keveyis. Its business model is centered on leveraging proprietary formulation platforms to create innovative delivery systems for its therapies, while also pursuing strategic partnerships, such as with American Regent for Gvoke VialDx.
Additional Information
Xeris Biopharma is positioned in the rare disease segment of biotechnology, with a focus on patient access and intellectual property protection. The company is actively developing its product pipeline, including XP-8121, which has received U.S. patent allowances, indicating potential growth and expansion in the U.S. market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
394
CEO
Mr. John P. Shannon
Country
United States
IPO Year
2018
Website
www.xerispharma.comXeris Biopharma Holdings, Inc. (XERS) Latest News & Analysis
Latest News
Quick Summary
Xeris Biopharma granted 304,975 restricted stock units to 90 new employees on April 1, 2026, under its Inducement Equity Plan, aiming to enhance its workforce.
Why It Matters
The grant of restricted stock units signals Xeris Biopharma's commitment to retaining talent, which can drive innovation and growth, potentially impacting future stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Xeris Biopharma Holdings, Inc. (XERS) presented at the Barclays 28th Annual Global Healthcare Conference, discussing key developments and strategies.
Why It Matters
Xeris Biopharma's presentation at a major healthcare conference can signal potential growth or strategic developments, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Xeris Biopharma Holdings, Inc. (XERS) held its Q4 2025 earnings call, providing updates on financial performance and business developments. Further details are available in the transcript.
Why It Matters
The earnings call provides insights into Xeris Biopharma's financial performance, growth prospects, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Xeris Biopharma Holdings, Inc. reported record revenues for Q4 and full year 2025. The company also provided financial guidance for 2026, highlighting a transformational year.
Why It Matters
Xeris Biopharma's strong financial results and positive guidance for 2026 indicate growth potential, which could attract investor interest and impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Xeris Biopharma (XERS) reported its quarterly performance for December 2025, suggesting a comparison of key metrics to Wall Street estimates and previous year results may be beneficial for investors.
Why It Matters
Xeris Biopharma's quarterly performance metrics relative to estimates and past results can indicate growth potential and market sentiment, impacting stock valuation and investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Xeris Biopharma (XERS) reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.03, compared to a loss of $0.03 per share the previous year.
Why It Matters
Xeris Biopharma's earnings beat estimates and show year-over-year improvement, signaling potential growth and investor confidence, which may positively impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About XERS Stock
What is Xeris Biopharma Holdings, Inc.'s (XERS) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Xeris Biopharma Holdings, Inc. (XERS) has a median price target of $10.00. The highest price target is $18.00 and the lowest is $8.00.
Is XERS stock a good investment in 2026?
According to current analyst ratings, XERS has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XERS stock?
Wall Street analysts predict XERS stock could reach $10.00 in the next 12 months. This represents a 68.9% increase from the current price of $5.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Xeris Biopharma Holdings, Inc.'s business model?
The company generates revenue through the commercialization of its biopharmaceutical products, which include Recorlev, Gvoke, and Keveyis. Its business model is centered on leveraging proprietary formulation platforms to create innovative delivery systems for its therapies, while also pursuing strategic partnerships, such as with American Regent for Gvoke VialDx.
What is the highest forecasted price for XERS Xeris Biopharma Holdings, Inc.?
The highest price target for XERS is $18.00 from Leland Gershell at Oppenheimer, which represents a 204.1% increase from the current price of $5.92.
What is the lowest forecasted price for XERS Xeris Biopharma Holdings, Inc.?
The lowest price target for XERS is $8.00 from David Amsellem at Piper Sandler, which represents a 35.1% increase from the current price of $5.92.
What is the overall XERS consensus from analysts for Xeris Biopharma Holdings, Inc.?
The overall analyst consensus for XERS is bullish. Out of 11 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are XERS stock price projections?
Stock price projections, including those for Xeris Biopharma Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 9, 2026 12:34 PM UTC